Report Highlights

The United States' Role in the Global Glycoprotein Supply Chain

The United States occupies the most strategically consequential position in the global glycoprotein supply chain, functioning simultaneously as the world's largest consumer market, a dominant producer of high-value recombinant glycoproteins, and the primary regulatory gatekeeper through FDA oversight. U.S. facilities operated by Amgen, Genentech, and AbbVie collectively account for an estimated 35–40% of global biologics-derived glycoprotein output by value. Monoclonal antibodies — heavily glycosylated therapeutic proteins — represent the single largest category, with U.S. manufacturers exporting finished drug product and bulk drug substance to Europe, Japan, and emerging markets. Approximately USD 32 billion in biologic exports from the U.S. annually include glycoprotein therapeutics as a core component.

On the import side, the U.S. relies on contract development and manufacturing organizations (CDMOs) based in Ireland, Germany, South Korea, and China for a meaningful share of upstream glycoprotein intermediates and formulated biologics. Lonza's Visp, Switzerland facility and Samsung Biologics in Incheon, South Korea supply bulk glycoprotein drug substance consumed by U.S. brand holders under toll-manufacturing arrangements. This dual role as exporter of finished therapeutics and importer of manufacturing capacity creates a structurally complex trade position that makes the U.S. glycoprotein market simultaneously an output powerhouse and a supply chain vulnerability — particularly for biologics whose active substance originates offshore.

Growth Drivers for U.S. Glycoprotein Trade and Production

Three supply chain-relevant drivers are accelerating U.S. glycoprotein production and trade capacity. First, the Inflation Reduction Act's biosimilar provisions and the BIOSECURE Act's restrictions on Chinese CDMOs are collectively pushing U.S. brand holders to reshoring production or nearshoring to Ireland and Canada — directly expanding domestic glycoprotein manufacturing footprint. Amgen's investment in continuous bioprocessing at its Thousand Oaks campus and AstraZeneca's new Maryland biologics facility represent over USD 3 billion in committed domestic capacity additions that will come online between 2025 and 2028, directly increasing U.S.-origin glycoprotein output volumes.

Second, the expanding therapeutic pipeline of bispecific antibodies and antibody-drug conjugates (ADCs) — both glycoprotein-dependent modalities — is driving demand for precision glycoengineering capabilities that U.S. biotech firms are uniquely positioned to supply. Third, the diagnostics segment, where glycoproteins serve as critical biomarkers and assay components, is benefiting from sustained post-pandemic investment in U.S. in-vitro diagnostics manufacturing. Abbott Laboratories and Thermo Fisher Scientific are scaling domestic glycoprotein reagent production, reducing reliance on European antigen suppliers and strengthening U.S. export competitiveness in diagnostic raw materials.

Supply Chain Risks and Trade Barriers

The U.S. glycoprotein supply chain carries three significant structural risks. First, dependency on single-source raw material suppliers for critical cell culture media components — particularly specialty lipids, recombinant growth factors, and animal-free hydrolysates — creates acute upstream vulnerability. Several of these inputs are sourced from a small number of European suppliers, including Merck KGaA's Life Science division in Germany, and supply disruptions during 2021 demonstrated that lead times can extend beyond six months, directly stalling glycoprotein batch production schedules. Cold-chain logistics constraints further compound this risk, as temperature-sensitive glycoprotein intermediates require specialized air freight that remains capacity-constrained.

Second, the U.S. faces material trade policy exposure. Section 301 tariffs on Chinese-origin biologics manufacturing equipment and consumables add cost friction to domestic capacity expansion, while the absence of a bilateral trade agreement with the European Union creates regulatory asymmetry for glycoprotein imports and exports — particularly for biosimilars seeking mutual recognition of manufacturing standards. FDA's requirement for U.S.-specific lot release testing, even for glycoproteins manufactured under EU GMP at validated overseas sites, adds 30 to 90 days to import timelines and raises effective landed cost for foreign-produced glycoprotein drug substances by 8–12%.

Trade and Investment Opportunities in the U.S. Glycoprotein Market

The most immediate investment opportunity lies in domestic glycoprotein CDMO capacity, driven directly by the BIOSECURE Act's effective exclusion of WuXi Biologics and related Chinese CDMOs from U.S. federally funded drug development programs. This regulatory shift has created a structural demand gap for U.S.-based or U.S.-allied biologics manufacturing, opening a capital deployment window estimated at USD 6–10 billion across new bioreactor capacity, fill-finish lines, and quality systems between 2025 and 2030. Companies including Thermo Fisher Scientific, Catalent, and Charles River Laboratories are actively expanding glycoprotein-capable manufacturing suites to capture displaced Chinese CDMO volumes.

A second major opportunity exists in glycoprotein-based diagnostics export. U.S. manufacturers hold strong intellectual property positions in recombinant glycoprotein antigens used in infectious disease and oncology diagnostics, and demand from Southeast Asia, Latin America, and the Middle East for U.S.-origin diagnostic components is growing at double-digit rates. Strategic partnerships between U.S. antigen producers and regional in-vitro diagnostics manufacturers in India and Brazil offer a route to export market penetration without requiring direct foreign manufacturing investment — an asset-light trade expansion model suited to the current regulatory and geopolitical environment.

Market at a Glance

Leading Market Participants

• Amgen Inc.
• AbbVie Inc.
• Genentech (Roche)
• Pfizer Inc.
• Johnson & Johnson (Janssen)
• AstraZeneca PLC
• Thermo Fisher Scientific
• Abbott Laboratories
• Merck & Co. Inc.
• Catalent Inc.

Regulatory and Trade Policy Environment

The U.S. glycoprotein market operates under a dense regulatory framework anchored by FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER), both of which impose glycan characterization requirements under 21 CFR Parts 600–610 for biologic glycoproteins. The Biologics Price Competition and Innovation Act (BPCIA) governs biosimilar glycoprotein entry, requiring demonstration of biosimilarity — including glycosylation profile comparability — before market authorization. The U.S.–Mexico–Canada Agreement (USMCA) provides preferential access for Canadian and Mexican biologics inputs, though glycoprotein trade flows under USMCA remain modest relative to transatlantic volumes. FDA's Emerging Technology Program actively supports novel glycoengineering manufacturing platforms seeking regulatory acceptance.

The BIOSECURE Act, if enacted in its current form, will prohibit U.S. federal agencies from contracting with companies using specified Chinese biotechnology service providers, directly reshaping glycoprotein CDMO sourcing strategies across the industry. Export control regulations under EAR (Export Administration Regulations) apply to certain glycoprotein production technologies and cell lines with dual-use potential. U.S. participation in the International Council for Harmonisation (ICH) Q6B guideline framework facilitates glycoprotein characterization standard alignment with EU and Japanese regulators, reducing — but not eliminating — duplicative testing requirements for glycoprotein products traded across these jurisdictions.

U.S. Glycoprotein Supply Chain Outlook to 2032

By 2032, the U.S. glycoprotein supply chain will be materially more domestically integrated than it is today, driven by geopolitical pressure, regulatory incentives, and continuous bioprocessing economics that favor scale at point of use. New single-use bioreactor facilities in North Carolina's Research Triangle, Massachusetts' Route 128 corridor, and the San Francisco Bay Area will add an estimated 500,000 liters of domestic glycoprotein-capable bioreactor capacity by 2030, reducing import dependency for bulk drug substance. Artificial intelligence-driven glycoengineering platforms — including those under development at Absci Corporation and Glycobia — will enable predictive glycoform optimization that compresses development timelines and reduces batch failure rates, strengthening U.S. competitive advantage in high-value therapeutic glycoproteins.

Trade flows will shift as U.S. biosimilar manufacturers gain FDA approval and begin exporting to price-sensitive emerging markets where branded glycoprotein therapeutics remain inaccessible. The U.S. will transition from a net importer of biosimilar glycoproteins to a competitive exporter in markets including Brazil, Saudi Arabia, and Indonesia by the late 2020s. Meanwhile, the diagnostics glycoprotein segment will deepen its export orientation, with U.S.-manufactured recombinant antigens and glycoprotein-based assay components supplying a growing share of global in-vitro diagnostics production chains — cementing the U.S. position as a value-added glycoprotein export hub rather than simply a consumption market.